Biointron has developed our own CHOK1-Fut8KO expression platform for afucosylated antibodies.

Biointron established a single-B cell antibody discovery platform based on microfluidic technology. Combined with our proprietary fast antibody expression platform, it has been proven to be fast and efficient in many projects.

Biointron has developed a successful method for discovering alpaca VHH for over 200 projects, using flexible immunization strategies and a robust phage display screening platform.

The Biointron team is excited to announce our participation in the Festival of Biologics 2024.

Biointron is excited to announce our participation in the upcoming AACR (American Association for Cancer Research) 2024 Annual Meeting.

Biointron is thrilled to announce our participation in the upcoming 23rd Annual PepTalk conference, scheduled for January 16-19 in San Diego.

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.